Deleted Tweets From Scott Gottlieb, R-D.C.

In the past two years, we’ve also taken a hard look at where else we can advance innovation and improve consumer protection across our vast portfolio. Our efforts related to cosmetics - which are still regulated under an 80-year-old law - is one example of this broader effort. https://t.co/BIedBkXjjg

Amid concerns about asbestos in cosmetics, we recently called on the cosmetic industry to take important new steps and to work with us to improve our overall framework for assuring the safety of cosmetic products. https://t.co/DXNvc5zlvt. https://t.co/k6nQHzJXNQ

The law focuses on ensuring that cosmetics are safe when properly labeled and used according to the label – #FDA does not review or approve cosmetics and their ingredients prior to sale, except color additives https://t.co/FfBlu33HLu. https://t.co/3QqKf5IMHT

#FDA also has efforts underway to bring oversight of the exploding dietary supplements market into the 21st Century. Our current initiatives are aimed at protecting the public from bad actors without burdening responsible companies https://t.co/KykFF3QWzs. https://t.co/qLz8D5KNEy

One area where #FDA can have a profound, generational, and transformative impact on human health - outweighing any single medical innovation or intervention that we could discover - is through advances in nutrition and diet. https://t.co/adk0MLCUFf

The Food Safety and Modernization Act of 2011 (FSMA) greatly enhanced #FDA’s ability to fulfill its critical role of protecting the food supply through an emphasis on preventing risk. During my tenure we’ve worked hard to implement #FSMA https://t.co/L8h8BbMHl5 https://t.co/r23Bu3uaUv

Over the past two years, we’ve also supported a number of major legislative efforts: To secure a more modern framework for the efficient regulation of diagnostic tests https://t.co/3Z7D3XhxZD, to reform how over-the-counter drugs come to market… https://t.co/nb6ayYQW9L

...and to reauthorize two animal drug user fee programs that enhance our ability to maintain a predictable, timely animal drug review process, foster innovation in drug development, expedite access to new therapies for food-producing and companion animals https://t.co/PuyF4oRiM6 https://t.co/KMhyl9h5ZO

Poor nutrition plays a role in heart disease, cancer and obesity and yet about 75% of the population has a diet low in vegetables, fruits, dairy and healthier oils; and most Americans exceed the recommended intake of added sugars, saturated fat and sodium https://t.co/ppSHHv0I7H.

Our 2018 Nutrition Innovation Strategy https://t.co/BdYfznEY8u seeks to reduce preventable death and disease caused by poor nutrition by ensuring that consumers have accurate useful info to make healthy food choices and also by fostering the development of healthier food options. https://t.co/V30FtdvY1o

I’m proud of how #FDA has stood strong in moments of crisis during the two years we worked together; leading a global investigation into impurities found in angiotensin II receptor blocker (ARB) drugs used to treat high blood pressure and heart failure https://t.co/wG1wy9QLKL...

FDA’s 2019 Strategic Approach for Combating AMR calls for fostering product development; supporting antimicrobial stewardship; enhancing AMR surveillance/monitoring; and advancing regulatory science to facilitate product development https://t.co/hOUM5toSZR. https://t.co/sp7RJc6AZk

…dedicating ourselves to mitigating the drug and device shortages in the aftermath of the storm in Puerto Rico https://t.co/K8xx3uWZUe; and maintaining critical functions and protecting the public during an historic government shutdown https://t.co/v2hwCg2r4g among other moments https://t.co/LhYxyyjmt5

Antimicrobial resistance occurs when microbes (e.g., bacteria, viruses, fungi) resist a drug - they aren’t killed/their growth isn’t stopped, so we lose our ability to effectively treat these infections. Addressing it requires an all-hands on deck, multi-faceted initiative. https://t.co/VzJl9il0dH

But our most vexing public health challenges remains the crisis of addiction to opioids and addiction to nicotine. Let’s look at opioids first, the largest and most complex public health tragedy our nation has ever faced, requiring decisive new steps by #FDA, on multiple fronts. https://t.co/2NT4lkh3D3

To jumpstart development of an over-the counter version of life-saving naloxone, which reverses an opioid overdose, FDA did unprecedented work - developing a model Drug Facts Label that sponsors can use to obtain approval to make naloxone OTC. https://t.co/n27rqO7Ktj https://t.co/qNNbZQjQBM

We’ve been working to prevent new opioid addiction; support treatments for opioid-use disorder and greater naloxone access; advance innovation in less risky non-opioid pain drugs; and increase enforcement/interdiction of illegal drugs https://t.co/Vso9eryJWi. https://t.co/RLbQPC6h2U

Owing to 2018 SUPPORT Act, we'll now require short-duration packaging for outpatient dispensing and are implementing authority to more easily detain, refuse and destroy illegal and dangerous drugs, including opioids, at our 9 International Mail Facilities https://t.co/y0dtAJSAiW. https://t.co/Z0W1d5hCnK

Companies that market opioids are now required to offer robust training on the safe prescribing of these products to all health care providers – it has also been broadened to include immediate-release in addition to extend-release, long-acting opioids https://t.co/6vgEUetYJG https://t.co/JmhGKUt4xf

And just last week I told Congress that #FDA needs a new standard for future approvals of new opioid drugs to ensure they offer a comparative advantage over existing opioids already approved to treat the same condition https://t.co/6c5Fm1D3Cy.

In the past two years, we’ve also taken a hard look at where else we can advance innovation and improve consumer protection across our vast portfolio. Our efforts related to cosmetics - which are still regulated under an 80-year-old law - is one example of this broader effort. https://t.co/BIedBkXjjg

Amid concerns about asbestos in cosmetics, we recently called on the cosmetic industry to take important new steps and to work with us to improve our overall framework for assuring the safety of cosmetic products. https://t.co/DXNvc5zlvt. https://t.co/k6nQHzJXNQ

The law focuses on ensuring that cosmetics are safe when properly labeled and used according to the label – #FDA does not review or approve cosmetics and their ingredients prior to sale, except color additives https://t.co/FfBlu33HLu. https://t.co/3QqKf5IMHT

#FDA also has efforts underway to bring oversight of the exploding dietary supplements market into the 21st Century. Our current initiatives are aimed at protecting the public from bad actors without burdening responsible companies https://t.co/KykFF3QWzs. https://t.co/qLz8D5KNEy

One area where #FDA can have a profound, generational, and transformative impact on human health - outweighing any single medical innovation or intervention that we could discover - is through advances in nutrition and diet. https://t.co/adk0MLCUFf

The Food Safety and Modernization Act of 2011 (FSMA) greatly enhanced #FDA’s ability to fulfill its critical role of protecting the food supply through an emphasis on preventing risk. During my tenure we’ve worked hard to implement #FSMA https://t.co/L8h8BbMHl5 https://t.co/r23Bu3uaUv

Over the past two years, we’ve also supported a number of major legislative efforts: To secure a more modern framework for the efficient regulation of diagnostic tests https://t.co/3Z7D3XhxZD, to reform how over-the-counter drugs come to market… https://t.co/nb6ayYQW9L

...and to reauthorize two animal drug user fee programs that enhance our ability to maintain a predictable, timely animal drug review process, foster innovation in drug development, expedite access to new therapies for food-producing and companion animals https://t.co/PuyF4oRiM6 https://t.co/KMhyl9h5ZO

Poor nutrition plays a role in heart disease, cancer and obesity and yet about 75% of the population has a diet low in vegetables, fruits, dairy and healthier oils; and most Americans exceed the recommended intake of added sugars, saturated fat and sodium https://t.co/ppSHHv0I7H.

Our 2018 Nutrition Innovation Strategy https://t.co/BdYfznEY8u seeks to reduce preventable death and disease caused by poor nutrition by ensuring that consumers have accurate useful info to make healthy food choices and also by fostering the development of healthier food options. https://t.co/V30FtdvY1o

I’m proud of how #FDA has stood strong in moments of crisis during the two years we worked together; leading a global investigation into impurities found in angiotensin II receptor blocker (ARB) drugs used to treat high blood pressure and heart failure https://t.co/wG1wy9QLKL...

FDA’s 2019 Strategic Approach for Combating AMR calls for fostering product development; supporting antimicrobial stewardship; enhancing AMR surveillance/monitoring; and advancing regulatory science to facilitate product development https://t.co/hOUM5toSZR. https://t.co/sp7RJc6AZk

…dedicating ourselves to mitigating the drug and device shortages in the aftermath of the storm in Puerto Rico https://t.co/K8xx3uWZUe; and maintaining critical functions and protecting the public during an historic government shutdown https://t.co/v2hwCg2r4g among other moments https://t.co/LhYxyyjmt5

Antimicrobial resistance occurs when microbes (e.g., bacteria, viruses, fungi) resist a drug - they aren’t killed/their growth isn’t stopped, so we lose our ability to effectively treat these infections. Addressing it requires an all-hands on deck, multi-faceted initiative. https://t.co/VzJl9il0dH

But our most vexing public health challenges remains the crisis of addiction to opioids and addiction to nicotine. Let’s look at opioids first, the largest and most complex public health tragedy our nation has ever faced, requiring decisive new steps by #FDA, on multiple fronts. https://t.co/2NT4lkh3D3

To jumpstart development of an over-the counter version of life-saving naloxone, which reverses an opioid overdose, FDA did unprecedented work - developing a model Drug Facts Label that sponsors can use to obtain approval to make naloxone OTC. https://t.co/n27rqO7Ktj https://t.co/qNNbZQjQBM

We’ve been working to prevent new opioid addiction; support treatments for opioid-use disorder and greater naloxone access; advance innovation in less risky non-opioid pain drugs; and increase enforcement/interdiction of illegal drugs https://t.co/Vso9eryJWi. https://t.co/RLbQPC6h2U

Owing to 2018 SUPPORT Act, we'll now require short-duration packaging for outpatient dispensing and are implementing authority to more easily detain, refuse and destroy illegal and dangerous drugs, including opioids, at our 9 International Mail Facilities https://t.co/y0dtAJSAiW. https://t.co/Z0W1d5hCnK

Companies that market opioids are now required to offer robust training on the safe prescribing of these products to all health care providers – it has also been broadened to include immediate-release in addition to extend-release, long-acting opioids https://t.co/6vgEUetYJG https://t.co/JmhGKUt4xf

And just last week I told Congress that #FDA needs a new standard for future approvals of new opioid drugs to ensure they offer a comparative advantage over existing opioids already approved to treat the same condition https://t.co/6c5Fm1D3Cy.